BIOLINERX LTD/S (NASDAQ:BLRX) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of BIOLINERX LTD/S (NASDAQ:BLRX) from a hold rating to a buy rating in a report released on Tuesday morning, ValuEngine reports.

BLRX has been the subject of a number of other research reports. Oppenheimer set a $13.00 target price on Alpine Immune Sciences and gave the company a buy rating in a report on Tuesday, March 19th. Maxim Group set a $9.00 target price on Brainstorm Cell Therapeutics and gave the company a buy rating in a report on Thursday, March 28th. HC Wainwright set a $25.00 target price on Onconova Therapeutics and gave the company a buy rating in a report on Tuesday, May 14th. Finally, Zacks Investment Research upgraded HANNOVER RUECK/S from a sell rating to a hold rating in a report on Friday, May 17th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $2.13.

NASDAQ:BLRX opened at $3.95 on Tuesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.12 and a current ratio of 5.12. The stock has a market capitalization of $32.01 million, a price-to-earnings ratio of -1.25 and a beta of 1.53. The company’s 50 day moving average is $0.66. BIOLINERX LTD/S has a fifty-two week low of $3.86 and a fifty-two week high of $27.60.

BIOLINERX LTD/S (NASDAQ:BLRX) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). As a group, equities research analysts forecast that BIOLINERX LTD/S will post -2.55 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. Menta Capital LLC purchased a new stake in shares of BIOLINERX LTD/S in the fourth quarter worth about $33,000. Two Sigma Securities LLC purchased a new stake in shares of BIOLINERX LTD/S in the fourth quarter worth about $25,000. Deutsche Bank AG purchased a new stake in shares of BIOLINERX LTD/S in the fourth quarter worth about $26,000. Delek Group Ltd. purchased a new stake in shares of BIOLINERX LTD/S in the first quarter worth about $92,000. Finally, NEXT Financial Group Inc boosted its stake in shares of BIOLINERX LTD/S by 82.5% in the second quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock worth $27,000 after buying an additional 33,000 shares during the last quarter. Institutional investors own 33.72% of the company’s stock.

BIOLINERX LTD/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Featured Article: How dollar cost averaging works

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.